The Phase 3 PEOPLE study evaluated the long-term effects of epicutaneous immunotherapy (EPIT) using the VIASKIN Peanut Patch, which delivers 250 μg peanut protein through the skin. This follow-up ...

"These results validate 'hypoallergens' as a potential therapeutic against peanut allergy, which we hope to use as vaccines in sensitive individuals." A hypoallergen treatment would expose a ...

Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy Now Available in the U.S. for Pediatric Ages 1 Through 3 Years Stallergenes Greer, a global leader in allergy therapeutics ...

SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months ...

Only two cases of chronic hiccups tied to eosinophilic esophagitis have previously been reported, the man's doctors say.

is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy. Palforzia is indicated for the mitigation of allergic reactions, including anaphylaxis, that may ...

It's spring and if you feel like your seasonal allergies are worse every year, it’s not just in your head (or your sinuses).

with a confirmed diagnosis of peanut allergy. Palforzia ® is the first and only U.S Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for the mitigation of allergic ...

Allergen Powder-dnfp] is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy.

LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced the launch of Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the U.S to treat toddler ...